BEAT - BioTelemetry: Still Undervalued Despite Pandemic Headwinds
Investment Thesis
BioTelemetry 5-year share price performance. Source: TradingView
BioTelemetry (NASDAQ:BEAT) stock has suffered worse than most from the effects of the coronavirus pandemic, falling by 47% in March from a 1-year peak of $54 to $28.5, but the stock has recovered well, despite management's warnings on lower-than-expected Q2 revenues and its withdrawal of FY20 guidance. The trading price at time of writing is $46.
I believe that the stock has further upside potential to realize and that the current price and market cap undervalue BioTelemetry - a medical technology company specializing in